Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Operating Leases (2021 - 2025)

Historic Operating Leases for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $20.4 million.

  • Janux Therapeutics' Operating Leases fell 626.44% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 626.44%. This contributed to the annual value of $21.3 million for FY2024, which is 759.61% down from last year.
  • Per Janux Therapeutics' latest filing, its Operating Leases stood at $20.4 million for Q3 2025, which was down 626.44% from $20.3 million recorded in Q2 2025.
  • Janux Therapeutics' Operating Leases' 5-year high stood at $24.5 million during Q4 2022, with a 5-year trough of $23000.0 in Q3 2021.
  • Its 5-year average for Operating Leases is $21.0 million, with a median of $22.6 million in 2024.
  • In the last 5 years, Janux Therapeutics' Operating Leases surged by 10464782.61% in 2022 and then plummeted by 844.07% in 2025.
  • Janux Therapeutics' Operating Leases (Quarter) stood at $23000.0 in 2021, then skyrocketed by 106604.35% to $24.5 million in 2022, then decreased by 6.18% to $23.0 million in 2023, then dropped by 7.6% to $21.3 million in 2024, then dropped by 4.21% to $20.4 million in 2025.
  • Its last three reported values are $20.4 million in Q3 2025, $20.3 million for Q2 2025, and $20.8 million during Q1 2025.